In metastatic castration-resistant prostate cancer (mCRPC), FAPI PET/CT may play a role in identifying tumor heterogeneity and detecting PSMA-negative lesions that do not respond to PSMA-targeted radionuclide therapy, potentially guiding alternative treatment approaches [80]. Here, FOLH1 is linked to neoplasm.